Summit Therapeutics Inc. (NASDAQ: SMMT) has gained peer-reviewed validation for the first global Phase 3 study of ivonescimab, with The Lancet Oncology publishing HARMONi results showing a statistically significant 48% reduction in the risk of progression or death when the PD-1×VEGF bispecific antibody was added to chemotherapy after third-generation EGFR-targeted therapy failed. The trial enrolled patients across 114 cancer centers and hospitals in Asia, Europe and North America with EGFR-mutated locally advanced or metastatic nonsquamous non-small-cell lung cancer whose disease had progressed following a third-generation EGFR tyrosine-kinase inhibitor. Median PFS was 6.8 months with ivonescimab plus chemotherapy compared with 4.4 months using placebo plus chemotherapy, producing a hazard ratio of 0.52 and a P value below 0.0001.
The publication arrives with a US regulatory deadline already approaching. FDA has assigned a November 14, 2026 PDUFA target date to Summit’s BLA for the same post-EGFR-TKI population, creating a relatively short interval between peer-reviewed publication and a potential decision on the first ivonescimab indication in Summit’s licensed territories. The pivotal uncertainty is overall survival: the primary analysis showed a favorable numerical trend but did not reach statistical significance, while later follow-up continues to mature and additional updated data are scheduled for presentation at the World Conference on Lung Cancer in September.
Why has conventional immunotherapy struggled after EGFR-targeted therapy?
EGFR-mutated NSCLC is biologically distinct from many smoking-associated lung cancers. Tumors driven by activating EGFR mutations can respond dramatically to EGFR tyrosine-kinase inhibitors, but once resistance develops, conventional PD-1 or PD-L1 checkpoint therapy has historically delivered less consistent benefit than it does in molecularly unselected NSCLC.
Several biological explanations have been proposed, including differences in tumor mutational burden, immune-cell infiltration and the immunosuppressive microenvironment surrounding EGFR-driven tumors. This has made the post-TKI treatment setting a difficult test for checkpoint inhibitors and a significant unmet need once targeted options are exhausted or no longer effective.
Ivonescimab is designed to address that problem by combining PD-1 blockade with VEGF inhibition in one bispecific molecule. VEGF is best known for promoting angiogenesis, but it also contributes to an immunosuppressive tumor microenvironment through effects on immune-cell trafficking and function. Blocking PD-1 and VEGF simultaneously could therefore both reactivate T cells and alter the vascular and immune environment preventing those cells from functioning effectively.
Why does one molecule targeting PD-1 and VEGF differ from simply administering two separate drugs?
Ivonescimab is engineered so PD-1 and VEGF binding occur within one tetravalent bispecific construct. Akeso and Summit argue that this architecture can concentrate VEGF-blocking activity in the tumor microenvironment where PD-1-expressing immune cells are present while maintaining the pharmacological advantages of checkpoint inhibition.
That could theoretically improve the therapeutic index compared with administering a systemic anti-PD-1 antibody and a separate VEGF inhibitor, although direct randomized evidence establishing superiority over such a two-drug immunotherapy/antiangiogenic strategy is not provided by HARMONi. The Phase 3 comparator was placebo plus platinum-doublet chemotherapy.
The significance of HARMONi is therefore more focused. It shows that adding this integrated PD-1×VEGF mechanism to chemotherapy meaningfully delayed disease progression in an EGFR-mutated population where traditional checkpoint approaches have struggled to establish clear Phase 3 benefit.
How convincing is the global nature of HARMONi?
This point matters strategically because much of ivonescimab’s earlier success came from China. HARMONi was conducted across Asia, Europe and North America at 114 sites, making it a critical test of whether the treatment effect translated outside the patient populations supporting Akeso’s Chinese approvals.
The primary PFS benefit was consistent across prespecified subgroups, while Summit has separately reported that updated overall-survival data in Western patients produced an OS hazard ratio of 0.76, described as consistent with the global population. Those updated survival findings will require fuller presentation before they can be interpreted with the same confidence as the published primary PFS result.
Global reproducibility is especially important for FDA because ethnic, treatment-pattern and subsequent-therapy differences can complicate reliance on trials conducted predominantly in one region. HARMONi was designed specifically to provide the multiregional evidence Summit needs for its Western regulatory strategy.
Why does overall survival remain the central unresolved issue?
PFS tells clinicians that disease progression or death occurred later with ivonescimab, but a therapy can improve radiographic disease control without ultimately extending life if later treatments compensate for the difference or if toxicity offsets part of the benefit.
At the primary OS analysis, ivonescimab showed a positive survival trend but did not cross the prespecified statistical threshold. Summit has emphasized that survival data remain immature and has continued following patients, with updated analysis expected at WCLC 2026.
This does not erase the highly significant PFS result. FDA can approve oncology medicines based on strong progression-free survival evidence when the total clinical benefit-risk profile supports doing so. It does mean that claims about ivonescimab extending survival in this global HARMONi population would currently overstate the published evidence.
The distinction is particularly relevant because separate Chinese trials have already demonstrated statistically significant OS benefits in other ivonescimab settings, including HARMONi-A and HARMONi-6. Those results strengthen confidence in the molecule broadly but cannot substitute for the survival endpoint in this specific global population.
What does the safety profile say about combining VEGF and PD-1 biology?
VEGF blockade can increase bleeding, hypertension and other vascular complications, while PD-1 inhibition can generate immune-mediated adverse events. Combining both mechanisms therefore creates obvious questions around whether enhanced efficacy comes with excessive toxicity.
In HARMONi, Summit described the overall safety profile as manageable and consistent with previous ivonescimab experience. Treatment-related Grade 3 to 5 hemorrhage events occurred in fewer than 1% of patients receiving ivonescimab plus chemotherapy.
That low rate is relevant because serious bleeding represents one of the clearest theoretical liabilities of incorporating VEGF blockade. FDA will nevertheless evaluate the complete adverse-event dataset rather than one selected toxicity, including treatment discontinuations, hypertension, proteinuria, immune-related complications and chemotherapy-associated effects.
A bispecific only creates an advantage if bringing both mechanisms together produces enough efficacy without turning two manageable safety profiles into a less manageable combined one.
Why is the November 14 FDA decision strategically important for Summit?
Summit licenses ivonescimab across the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa, while Akeso retains other territories including China. More than 4,000 patients have received ivonescimab across clinical studies, and the companies are running or planning Phase 3 programmes across multiple lung cancer settings as well as colorectal, head-and-neck and other malignancies.
A first US approval would therefore validate not only HARMONi but Summit’s multibillion-dollar strategic commitment to a drug discovered and initially developed by Akeso. It would also place a PD-1×VEGF bispecific into direct competition with entrenched checkpoint franchises in Western oncology markets.
The publication strengthens the regulatory narrative by showing that the 48% progression-risk reduction has survived peer review and was generated in a genuinely multiregional study. Yet the story remains deliberately unfinished. HARMONi has answered the PFS question convincingly; the survival curve is still developing.
That makes the coming months unusually important. WCLC can clarify whether the OS trend is strengthening, while FDA must decide whether the existing totality of evidence is enough for approval by November 14. Ivonescimab has already demonstrated that dual PD-1 and VEGF targeting can delay progression after EGFR-TKI resistance. The remaining question is how much that advantage ultimately changes the entire disease course.
